Comparison
Lixisenatide vs. Selank
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
320367-13-3
129954-34-3
Molecular weight
4858.5 g/mol
751.85 g/mol
Half-life
3 h
0.3 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Thr-Lys-Pro-Arg-Pro-Gly-ProMechanism of action
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
5
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1